ALIFE 2

Based on trial findings, authors do not advise the use of LMWH in this population or screening for inherited thrombophilia in women with recurrent pregnancy loss.

An international, open-label RCT "showed no significant difference in livebirth rates in women with recurrent pregnancy loss and confirmed inherited thrombophilia after treatment with LMWH treatment when compared with standard care alone", write authors. Research in context ⤵️

New study: Many women with recurrent miscarriage are tested for inherited thrombophilia. If confirmed positive, daily subcutaneous low-molecular-weight heparin (LMWH) is given. This is despite an absence of evidence that such treatment is beneficial 🧵 hubs.li/Q01S2WvV0

Alongside decreasing the treatment burden and associated costs, "the results also mean that researchers can focus research on other solutions for recurrent pregnancy loss after decades of investigating anticoagulants", say @s_quenby and colleagues.

Always great to get an answer even if it’s negative treatment outcome. @uhbtrust recruited a record number of patients into the trial - big thanks to all the patients who participated, you have made an impact on thousands of women 👏 @s_quenby

Today the ALIFE2 Trial was published in @TheLancet - thank you to all the women who participated and colleagues who supported the trial authors.elsevier.com/c/1hAohV-4XL1xJ

📣Publication alert: finally published in @TheLancet , the ALIFE2 trial. So thankful to all women who participated and all colleagues who joined the study. LMWH does NOT improve live birth in women with #thrombophilia and #recurrent miscarriage. thelancet.com/pb-assets/Lanc…

MILESTONE ALERT: This week we reached a huge milestone. Over 300 women have now been randomised. We are so so close to finishing this important trial! Its the final countdown ... @WarwickCTU @s_quenby @MiddeldorpS

@MiddeldorpS @ALIFE2trial @INVENT_VTE Great trial. Critcal data.

@MiddeldorpS @ALIFE2trial @INVENT_VTE I’ve been waiting for the results!! :)

Happy news: we have seen a boost in randomizations in the @ALIFE2trial. Women with recurrent #miscarriage and #thrombophilia are allocated to #LMWH or standard of care. Lots of new #pregnancies and hope after lockdown 🥰 alife2study.org @INVENT_VTE

Another curve: Progress of the ALIFE2 study: A dynamic road towards more evidence. Slowly, but we are getting there! #thrombophilia #miscarriage #LMWH @ALIFE2trial @INVENT_VTE @s_quenby @ScheresLuuk @ThrombosisRese1 thrombosisresearch.com/article/S0049-…

Fantastic! Also in the global sites we have recruitments! We all keep up the good work. #thrombophilia #miscarriage #lmwh @INVENT_VTE @ALIFE2trial

A huge thank you to our teams @NorthMidNHS and @uclh for recruiting participants to the @ALIFE2trial this week. Keep up the fantastic work.

I know we can do this. Thank you to our ladies for taking part.

A huge thank you to the team at Liverpool Women's @LiverpoolWomens for recruiting your second participant to the @ALIFE2trial this week. Keep up the fantastic work! That's 275 women registered to participate in the UK now. We are so close to finding an answer!

Many thanks to our wonderful sites UHCW, Manchester and Liverpool @UHCW_RandD @MFH_Research @LiverpoolWomens for recruiting participants to the @ALIFE2trial this week. Your amazing work has helped us to recruit 400 participants internationally. Thank you so much

Fantastic! So very happy with @ALIFE2trial participants and investigators! @INVENT_VTE

MILESTONE ALERT: 400 women have now registered to participate in the trial. Thank you so much to our fantastic sites and wonderful participants for helping us to reach this amazing milestone. We are so close to answering this important question @s_quenby @MiddeldorpS @WarwickCTU

Thank you to all our sites for having a fantastic month recruiting in January. At the end of last week @nottmhospitals and @UHCW_RandD recruited 2 participants . That's an amazing 13 participants recruited in Jan. We cant wait to see what February brings